Xarelto (rivaroxaban) / J&J 
Welcome,         Profile    Billing    Logout  
 97 Diseases   247 Trials   247 Trials   14602 News 


«12...144145146147148149150151152153154...170171»
  • ||||||||||  rivaroxaban / Generic mfg.
    Clinical, Journal:  Randomized trial of rivaroxaban versus warfarin in the evaluation of progression of coronary atherosclerosis. (Pubmed Central) -  Jun 26, 2019   
    Warfarin, a vitamin K antagonist, is associated with systemic vascular calcification. We evaluated whether rivaroxaban (a direct oral factor Xa inhibitor with no interaction with vitamin K) will slow the progression in coronary plaque volumes compared with warfarin in patients with nonvalvular atrial fibrillation using coronary computed tomography angiography.
  • ||||||||||  Xarelto (rivaroxaban) / Bayer, J&J
    Journal:  Evaluation of activated charcoal and lipid emulsion treatment in model of acute rivaroxaban toxicity. (Pubmed Central) -  Jun 22, 2019   
    These observations demonstrate that coagulation FXa inhibitor probably has a cardioprotective effect against pressure-overload-induced atrial remodeling. Although the administration of either AC or LE alone or in combination resulted in a decrease in the mean values of PT and anti-Factor Xa, in case of rivaroxaban toxicity, but one-to-one comparison of the groups was not statistically significant.
  • ||||||||||  Xarelto (rivaroxaban) / Bayer, J&J
    Journal:  The role of rivaroxaban in left ventricular thrombi. (Pubmed Central) -  Jun 22, 2019   
    A bivariate analysis that simultaneously characterizes both risk and benefit demonstrates that riva- and dabi-based regimens were both favorable over VKA plus dual antiplatelet therapy among patients with atrial fibrillation undergoing PCI. No abstract available
  • ||||||||||  Journal:  Anticoagulation in Acute Coronary Syndrome: Review of Major Therapeutic Advances. (Pubmed Central) -  Jun 22, 2019   
    Different OACs have been tested as antithrombotic therapy after ACS in combination with single or DAPT and led to a modest reduction in ischemic events. Further studies evaluating NOACs in combination with single antiplatelet therapy or shorter duration of triple antithrombotic therapy are warranted.
  • ||||||||||  Xarelto (rivaroxaban) / Bayer, J&J, Pradaxa (dabigatran etexilate) / Boehringer Ingelheim, Eliquis (apixaban) / BMS
    Clinical, Journal:  Effectiveness and Safety of Non-Vitamin K Oral Anticoagulants in Comparison to Phenprocoumon: Data from 61,000 Patients with Atrial Fibrillation. (Pubmed Central) -  Jun 20, 2019   
    All pivotal trials have evaluated non-vitamin K oral antagonists (NOACs) against warfarin...After adjusting for baseline confounders, all three NOACs tested had significantly lower risks of stroke/SE compared with phenprocoumon (apixaban-HR: 0.77, 95% CI: 0.66-0.90; dabigatran-HR: 0.74, 95% CI: 0.60-0.91; rivaroxaban-HR: 0.86, 95% CI: 0.76-0.97)...All three NOACs showed reduced risk of intracranial bleeding compared with phenprocoumon. Reduced doses of NOACs were predominantly used in patients with advanced age and comorbidities with generally similar effectiveness and safety benefits compared with phenprocumon as standard-dose NOACs.
  • ||||||||||  Journal:  International Council for Standardization in Haematology (ICSH) Recommendations for Laboratory Measurement of Direct Oral Anticoagulants. (Pubmed Central) -  Jun 20, 2019   
    The committee addressed the use and limitations of screening tests such as prothrombin time, activated partial thromboplastin time as well as viscoelastic measurements of clotting blood and point of care methods. Additionally, the committee provided recommendations for the proper validation or verification of performance of laboratory assays prior to implementation for clinical use, and external quality assurance to provide continuous assessment of testing and reporting method.
  • ||||||||||  Xarelto (rivaroxaban) / Bayer, J&J, Eliquis (apixaban) / BMS
    Journal:  Bleeding rates of Veterans taking apixaban or rivaroxaban for atrial fibrillation or venous thromboembolism. (Pubmed Central) -  Jun 19, 2019   
    Observed bleeding for both rivaroxaban and apixaban in the Veteran population exceeded the rates reported by the literature when used for atrial fibrillation (1.96% vs. 0.15%, p < 0.05; 1.08% vs. 0.16%, p < 0.05) but the opposite was seen for long term venous thromboembolism (VTE) treatment (3.97% vs. 8.03%, p < 0.0001; 0.14% vs. 15.51%, p < 0.0001) or extended VTE prophylaxis (0.07% vs 5.98%, p < 0.0001; 0.07% vs 1.88%, p < 0.01). Results from this study suggest these agents impart similar levels of risk, but variations in bleeding risk between the Veteran population and the patients in the original clinical trials may exist.
  • ||||||||||  Xarelto (rivaroxaban) / Bayer, J&J, Pradaxa (dabigatran etexilate) / Boehringer Ingelheim, Eliquis (apixaban) / BMS
    Clinical, Journal:  Exploring the effect of factor Xa inhibitors on rotational thromboelastometry: a case series of bleeding patients. (Pubmed Central) -  Jun 19, 2019   
    Although not statistically significant, PT appears to have a higher correlation with direct Xa inhibitor activity than EXTEM-CT. Further research with larger samples is necessary to clarify the differences between ROTEM and standard assays in detecting DOAC activity.
  • ||||||||||  PK/PD data, Journal:  Pharmacokinetic and Pharmacodynamic Drug Monitoring of Direct-Acting Oral Anticoagulants: Where Do We Stand? (Pubmed Central) -  Jun 19, 2019   
    For decades, oral anticoagulation has been based on vitamin K antagonist such as warfarin, which requires pharmacodynamic (PD) drug monitoring to guide the therapy...For the direct thrombin inhibitor dabigatran etexilate, a calibrated diluted thrombin time or ecarin clotting time can be used, whereas for anti-factor Xa drugs such as rivaroxaban, apixaban, edoxaban, and betrixaban, calibrated anti-factor Xa assays are appropriate...So far, not many clinical data have been published about the potentially beneficial effects of PD monitoring for dose individualization. The assay platforms for PD monitoring are present in many clinical laboratories, but efforts are needed to validate and standardize available assays to perform appropriate clinical trials.
  • ||||||||||  Xarelto (rivaroxaban) / Bayer, J&J, Pradaxa (dabigatran etexilate) / Boehringer Ingelheim
    Clinical, Review, Journal:  Embolic strokes of undetermined source: theoretical construct or useful clinical tool? (Pubmed Central) -  Jun 18, 2019   
    ...NAVIGATE ESUS, the first phase III randomized-controlled, clinical trial (RCT) comparing rivaroxaban (15 mg daily) with aspirin (100 mg daily), was prematurely terminated for lack of efficacy after enrollment of 7213 patients...RE-SPECT ESUS was the second phase III RCT that compared the efficacy and safety of dabigatran (110 or 150 mg, twice daily) to aspirin (100 mg daily)...The potential clinical utility of ESUS may be challenged since the concept failed to identify patients who would benefit from anticoagulation therapy. Compared with the former diagnosis of CS, ESUS patients required thorough investigations; more comprehensive diagnostic work-up than is requested in current ESUS diagnostic criteria may assist clinicians in uncovering the source of brain embolism in CS patients and individualize treatment approaches.
  • ||||||||||  Xarelto (rivaroxaban) / Bayer, J&J, Pradaxa (dabigatran etexilate) / Boehringer Ingelheim, Eliquis (apixaban) / BMS
    Clinical, Review, Journal:  Patient-focused interventions to support vulnerable people using oral anticoagulants: a narrative review. (Pubmed Central) -  Jun 18, 2019   
    Many interventions reported a significant positive impact on patients' knowledge, reduction in the number of adverse events caused by hemorrhage, and better INR control. More research on patient-focused interventions is needed that includes patients with limited health literacy, those from CALD backgrounds, and family members and caregivers of patients taking oral anticoagulants.
  • ||||||||||  rivaroxaban / Generic mfg., warfarin / Generic mfg.
    Enrollment open, Trial completion date, Trial primary completion date:  RISE MS: RIvoraxaban in Mitral Stenosis (clinicaltrials.gov) -  Jun 17, 2019   
    P3,  N=100, Recruiting, 
    More research on patient-focused interventions is needed that includes patients with limited health literacy, those from CALD backgrounds, and family members and caregivers of patients taking oral anticoagulants. Not yet recruiting --> Recruiting | Trial completion date: Apr 2020 --> Jun 2021 | Trial primary completion date: Apr 2020 --> May 2021
  • ||||||||||  Xarelto (rivaroxaban) / Bayer, J&J, Pradaxa (dabigatran etexilate) / Boehringer Ingelheim, Eliquis (apixaban) / BMS
    Clinical, Journal:  Trends and Variation in Oral Anticoagulant Choice in Patients with Atrial Fibrillation, 2010-2017. (Pubmed Central) -  Jun 15, 2019   
    NOAC prescriptions have increased substantially among incident OAC users with nonvalvular AF, predominantly driven by increased prescription of apixaban. Warfarin and apixaban were generally preferred for elderly patients, patients with higher stroke or bleeding risk, and patients with more comorbidities.
  • ||||||||||  Xarelto (rivaroxaban) / Bayer, J&J, Pradaxa (dabigatran etexilate) / Boehringer Ingelheim, Eliquis (apixaban) / BMS
    Clinical, Journal:  Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and thrombocytopenia. (Pubmed Central) -  Jun 15, 2019   
    Warfarin and apixaban were generally preferred for elderly patients, patients with higher stroke or bleeding risk, and patients with more comorbidities. Our findings indicate that in AF patients with mild thrombocytopenia, anticoagulation with NOAC at reduced doses seems to be safe and effective.
  • ||||||||||  Clinical, Journal:  Anticoagulant therapy in the elderly. (Pubmed Central) -  Jun 15, 2019   
    Consideration of benefit and risk is often complicated in elderly patients, but this should be repeatedly done during the therapy. Key words: anticoagulation therapy - apixaban - dabigatran - edoxaban - fragile patient - geriatrics - rivaroxaban.
  • ||||||||||  Xarelto (rivaroxaban) / Bayer, J&J, Pradaxa (dabigatran etexilate) / Boehringer Ingelheim, Eliquis (apixaban) / BMS
    Review, Journal:  Perioperative handling of anticoagulation (Pubmed Central) -  Jun 7, 2019   
    Thus, undifferentiated bridging for all patients with atrial fibrillation with anticoagulant treatment is not recommended. Instead, the indications for a perioperative bridging should be decided according to individual risk profiles.
  • ||||||||||  Savaysa (edoxaban) / Daiichi Sankyo
    Trial completion, Preclinical:  PADOASU: In Vitro Diagnostic Test for DOAC in Urine (clinicaltrials.gov) -  Jun 7, 2019   
    P=N/A,  N=880, Completed, 
    Registerd 14 May 2015; Retrospectively Registered. Recruiting --> Completed
  • ||||||||||  Clinical, Journal:  Laboratory Monitoring of Non-Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation: A Review. (Pubmed Central) -  Jun 5, 2019   
    Randomized trials show that unmonitored NOAC therapy is at least as effective as and safer than dose-adjusted warfarin for stroke prevention in patients with nonvalvular atrial fibrillation...Further research is required to determine whether routine laboratory monitoring might provide a net benefit for patients. Until such data are available, clinicians should continue to prescribe NOACs in fixed doses without routine monitoring.